Abstracts tagged "Infection"

Abstract Number: 1587 • 2017 ACR/ARHP Annual Meeting
Mycobacterial Infection in Systemic Lupus Erythematosus: Clinical Significance and Associated Factors. Data from the Registry of Patients with SLE of the Spanish Society of Rheumatology (RELESSER)
Ana Lois-Iglesias¹, Víctor del Campo-Pérez², Iñigo Rúa-Figueroa³, Coral Mouriño-Rodriguez⁴, Francisco Javier López Longo⁵, María Galindo⁶, Jaime Calvo-Alen⁷, Jesús Ibañez Ruán⁸, Alejandro Olivé⁹, Rafael-Benito Melero González⁴, Antonio Fernandez-Nebro¹⁰, José Antonio Bernal¹¹, Celia Erausquin¹², Eva Tomero¹³, Maria Loreto Horcada¹⁴, Esther Uriarte¹⁵, Mercedes Freire¹⁶, Carlos Alberto Montilla-Morales¹⁷, Ana Sánchez Atrio¹⁸, Alina Boteanu¹⁹, Elvira Diez Alvarez²⁰, Javier Narváez²¹, Víctor Martínez Taboada²², Lucía Silva Fernández²³, Esther Ruiz Lucea²⁴, Jose Luis Andreu²⁵, José Hernández Beiraín²⁶, Marian Gantes²⁷, Blanca Hernández-Cruz²⁸, Jose Javier Perez Venegas²⁹, Ángela Pecondón Español³⁰, Nuria Lozano-Rivas³¹, Monica Ibanez Barcelo³², Gema Bonilla³³, Vicente Torrente³⁴, Ivan Castellví³⁵, Juan José Alegre³⁶, Mireia Moreno³⁷, José Luis Marenco de la Fuente³⁸, Cesar Magro-Checa³⁹, Tomás Vázquez Rodríguez⁴⁰, Victor Quevedo⁴¹, Patricia Richi⁴², Maria Teresa Oton Sanchez⁴³ and JM Pego-Reigosa⁴⁴, ¹Rheumatology, University Hospital A Coruña, A Coruña, Spain, ²Preventive Medicine and Epidemiology, EOXI Vigo, Vigo, Spain, ³Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ⁴Rheumatology, EOXI Vigo, Vigo, Spain, ⁵Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, ⁶Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ⁷Rheumatology, Txagorritxu Hospital, Araba, Vitoria, Vitoria, Spain, ⁸POVISA, Rheumatology, Vigo, Spain, ⁹Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁰Rheumatology, Regional Universitary Hospital of Málaga, Malaga, Spain, ¹¹Reumatología, Hospital Universitario del Vinalopó, Elche, Spain, ¹²Rheumatology, Hospital de Gran Canaria Dr Negrin, Las Palmas GC, Spain, ¹³Hospital La Princesa. Madrid., Madrid, Spain, ¹⁴Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁵Reumatología, Hospital de Donosti, Donosti, Spain, ¹⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ¹⁷Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ¹⁸University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology Department, Alcalá de Henares, Madrid, Spain, ¹⁹University Hospital Ramón y Cajal, Madrid, Spain, ²⁰Complejo Asistencial Universitario de León. León. Spain, León, Spain, ²¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²²Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, ²³Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²⁴Hospital de Basurto, Bilbao, Spain, ²⁵Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²⁶Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ²⁷Rheumatology, Hospital Universitario de Canarias, La Laguna; Tenerife, Spain, ²⁸Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ²⁹Rheumatology, Hospital de Jerez de la Frontera, Jerez de la Frontera, Spain, ³⁰Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ³¹Rheumatology, Hospital Virgen de la Arrixaca, murcia, Spain, ³²H. Son Llatzer, Palma de Mallorca, Spain, ³³Hospital Universitario La Paz, Madrid, Spain, ³⁴Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain, ³⁵Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ³⁶Sección de Reumatología Hospital Universitario Dr Peset Valencia, Valencia, Spain, ³⁷Rheumatology, Hospital Universitari Parc Taulí, Sabadell, Spain, ³⁸Rheumatology, Hospital de Valme, Seville, Spain, ³⁹Department of Rheumatology, Leiden University Medical Center, Leiden, Spain, ⁴⁰Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ⁴¹Rheumatology, Hospital de Monforte, Lugo, Spain, ⁴²Hospital Infanta Sofía, Madrid, Spain, ⁴³Rheumatology Department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, ⁴⁴Rheumatology Section, Hospital de Meixoeiro, Pontevedra, Spain, Vigo, Spain
Background/Purpose: The aim of this work is to study the prevalence of mycobacterial infection (M.I.), the associated factors and their clinical significance in patients included…
Abstract Number: 1967 • 2017 ACR/ARHP Annual Meeting
Strongyloides Screening in Immunocompromised Immigrant Rheumatology Patients
Sahitya Mallipeddi¹, Christina Coyle² and Beverly Johnson¹, ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Infectious Diseases, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Strongyloides Stercoralis is a helminthic infection that is usually chronic and asymptomatic and may persist undiagnosed for decades. Patients from strongyloides endemic areas (tropics…
Abstract Number: 1972 • 2017 ACR/ARHP Annual Meeting
Causes of Death in 350 Patients with Systemic Autoimmune Rheumatic Diseases
Juan Gabriel Ovalles-Bonilla^1,2, Olaia Fernández-Berrizbeitia³, Julia Martínez-Barrio¹, Larissa Valor¹, Diana Hernández¹, Iustina Janta¹, Belen Serrano¹, Claudia Saez¹, Roberto Gonzalez¹, María Correyero¹, Leticia García¹, Ana López-Cerón¹, Alicia Silva¹, Juan Carlos Nieto¹, Carlos González^1,4, Indalecio Monteagudo¹ and Francisco Javier López Longo^1,4, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital Universitario Basurto, Bilbao, Spain, ⁴Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The major SARD have an increased mortality compared to the general population. It is well known that the main causes of death in Systemic…
Abstract Number: 2082 • 2017 ACR/ARHP Annual Meeting
Clinical Presentation, Management, and Prognosis of Pseudogout in Prosthetic Joint Implant Patients: A Retrospective Study
Merit P. George¹, Floranne C. Ernste², Aaron J. Tande³, Douglas R. Osmon³, Tad M. Mabry⁴ and Elie F. Berbari³, ¹Mayo Clinic School of Medicine, Rochester, MN, ²Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ³Division of Infectious Diseases, Mayo Clinic Rochester, Rochester, MN, ⁴Division of Orthopedic Surgery, Mayo Clinic Rochester, Rochester, MN
Background/Purpose: The prevalence of total knee arthroplasty (TKA) and total hip arthroplasty (THA) has risen considerably in the U.S. There has been a relative lack…
Abstract Number: 271 • 2017 ACR/ARHP Annual Meeting
The Trend of Incidence Rate, Frequency and HLA Phenotype of Reactive Arthritis and Uveitis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy: A 20-Year, Two-Center Retrospective Study
Yoshinori Taniguchi¹, Satoshi Inotani², Hirofumi Nishikawa², Kosuke Inoue³, Taro Horino², Takashi Karashima⁴, Yasuhiko Yoshinaga⁵ and Yoshio Terada³, ¹Endocrinology, Metabolism,Nephrology and Rheumatology, Kochi University, Kochi, Japan, ²Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School, Nankoku, Japan, ³Kochi University, Nankoku, Japan, ⁴Urology, Kochi University, Nankoku, Japan, ⁵Kurashiki Medical Center, Kurashiki, Japan
Background/Purpose: Intravesical instillation of Bacillus Calmette-Guerin (iBCG) is used as an effective immunotherapy of bladder cancer. However it may have, as adverse event, a reactive…
Abstract Number: 2140 • 2017 ACR/ARHP Annual Meeting
Infections and Medications Associated with Onset of Myositis in Myovision, a National Myositis Patient Registry
Lisa G Rider¹, Payam Noroozi Farhadi¹, Nastaran Bayat¹, Jesse Wilkerson², Abdullah Faiq¹, John McGrath², Hermine I. Brunner³, Bob Goldberg⁴ and Frederick W Miller¹, ¹Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ²Social and Scientific Systems, Inc., Durham, NC, ³Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴The Myositis Association, Alexandria, VA
Background/Purpose: Myositis is a rare systemic autoimmune disease with suspected environmental and genetic risk factors, but little is known about specific infections and medications that…
Abstract Number: 276 • 2017 ACR/ARHP Annual Meeting
Follow-up of Patients with Musculoskeletal Manifestations Related to Chikungunya Fever
Paula Murari-Nascimento¹, Ana Beatriz Vargas-Santos², Natalia Fortes¹, Heruza Zogbi³, Otília Santos³, Patricia Brasil³, Guilherme Calvet³, Rogério Valls³, Carlos Andrade³, Andre Siqueira³, Geraldo Castelar-Pinheiro², Letícia Pereira¹ and Rodrigo B. Chaves-Amorim⁴, ¹State University of Rio de Janeiro, Rio de Janeiro, Brazil, ²Internal Medicine - Rheumatology, State University of Rio de Janeiro, Rio de Janeiro, Brazil, ³Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation – FIOCRUZ, Rio de Janeiro, Brazil, ⁴Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil
Background/Purpose: Chikungunya fever (CHIK) has joint involvement as a striking characteristic, which may persist for months. This study aimed to better understand the clinical impact of…
Abstract Number: 2150 • 2017 ACR/ARHP Annual Meeting
Serum Microrna-1 Can be a Predictive Marker for Disease Activity of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Yumiko Sugiyama, Ryusuke Yoshimi, Yosuke Kunishita, Daiga Kishimoto, Yohei Kirino and Hideaki Nakajima, Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Although intensive immunosuppressive treatment are necessary for the severe cases with polymyositis (PM)/dermatomyositis (DM), the prognostic factors or disease activity indices for PM/DM have…
Abstract Number: 282 • 2017 ACR/ARHP Annual Meeting
The Value of Imaging As an Early Noninvasive Test for Prosthetic Joint Septic Arthritis
Kevin Byrne¹, Mary Louise Fowler², Sarah Lieber³, Robert Shmerling⁴ and Ziv Paz³, ¹Boston University School of Medicine, Boston, MA, ²2Boston University School of Medicine, Boston, MA, ³Beth Israel Deaconess Medical Center, Boston, MA, ⁴Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Medical imaging is commonly obtained in evaluating patients with suspected prosthetic joint septic arthritis (PJSA); it may be helpful to detect other pathology in…
Abstract Number: 2333 • 2017 ACR/ARHP Annual Meeting
Adjudication of Infections from the Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (PHARMACHILD) Treated with Biologic Agents and/or Methotrexate with a Focus on Opportunistic Infections
Joost Swart¹, Gabriella Giancane^1,2, Elio Castagnola¹, Andreas Groll¹, Gerd Horneff¹, Hans-Iko Huppertz¹, Daniel J Lovell³, Tom Wolfs¹, Michaël Hofer¹, Ekaterina Alexeeva¹, Violeta Vladislava Panaviene¹, Susan Nielsen¹, Jordi Anton¹, Florence Uettwiller¹, Valda Stanevicha¹, Maria Trachana¹, Fabrizio De Benedetti¹, Constantin Ailioaie¹, Elena Tsitsami¹, Sylvia S.M. Kamphuis¹, Troels Herlin¹, Pavla Dolezalová¹, Gordana Susic¹, Berit Flato¹, Flavio Sztajnbok¹, Elena Fueri⁴, Francesca Bovis⁵, Francesca Bagnasco¹, Angela Pistorio¹, Alberto Martini⁶, Nico Wulffraat⁷ and Nicolino Ruperto⁶, ¹Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, ²Pediatria II, Reumatologia - PRINTO, Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, ³Rheumatology, PRCSG - Cincinnati Children's Hospital Medical Center, Cinncinnati, OH, ⁴Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, ⁵Università degli Studi di Genova, Genoa, Italy, ⁶Istituto Giannina Gaslini, Genoa, Italy, ⁷Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands
Background/Purpose: Pharmachild is a pharmacovigilance registry on children with JIA treated mainly with biologics ± methotrexate (MTX). Little evidence exists in literature about the role…
Abstract Number: 386 • 2017 ACR/ARHP Annual Meeting
Analysis of the Effectiveness of Immunization with Pneumococcal Polysaccharide Vaccine in Children with Juvenile Idiopathic Arthritis
Ekaterina Alexeeva^1,2, Tatiana Dvoryakovskaya¹, Rina Denisova¹, Olga Lomakina¹, Ksenia Isaeva¹, Margarita Soloshenko¹, Anna Karaseva¹, Nikolay Mayansky³, Irina Zubkova³, Darija Novikova⁴, Anna Gayvoronskaya⁴, Natalia Tkachenko⁴, Marika Ivardava⁴, Firuza Shakhtakhtinskaya⁴ and Marina Fedoseenko⁴, ¹Reumatology department, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ²Pediatrics, The Federal State Autonomous Educational Institution of Higher Education The First Moscow State Medical University named after I.M. Sechenov Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation, ³Clinical laboratory, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ⁴Department of Vaccine Prevention, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most frequent and most disabling rheumatic diseases in childhood. Children suffering from JIA receiving immunosuppressive and…
Abstract Number: 2410 • 2017 ACR/ARHP Annual Meeting
Serious Infection Risk in Patients with Rheumatoid Arthritis Compared to Patients with Non-Inflammatory Rheumatic Diseases: A US National Cohort Study
Bella Y. Mehta¹, Sofia Pedro², Gulsen Ozen³ and Kaleb Michaud⁴, ¹Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Rheumatology, Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Serious infections (SI) in patients with rheumatoid arthritis (RA) are a perpetual concern. We compared the risk by first and recurrent SIs in patients…
Abstract Number: 496 • 2017 ACR/ARHP Annual Meeting
Repeated Rituximab Infusions for the Therapy of Rheumatoid Arthritis Is Not Associated with Increased Rates of Serious Infections
Dimitrios A. Pappas^1,2, George W. Reed^1,3, Steve Zlotnick⁴, Jennie Best⁴, Robert Magner³, Gioia Persuitte¹ and Jeffrey D Greenberg^1,5, ¹Corrona, LLC, Southborough, MA, ²Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ³University of Massachusetts Medical School, Worcester, MA, ⁴Genentech, Inc., South San Francisco, CA, ⁵NYU School of Medicine, New York, NY
Background/Purpose: Extended observations in clinical trials have not demonstrated an increased risk of serious infection events (SIE) in patients with rheumatoid arthritis (RA) treated with…
Abstract Number: 2428 • 2017 ACR/ARHP Annual Meeting
Epstein-Barr Virus Infection and Epstein-Barr Virus　Nuclear Antigen 1 Variants in the Synovial Tissue of Rheumatoid Arthritis
Shotaro Masuoka¹, Natsuko Kusunoki¹, Shinichi Kawai² and Toshihiro Nanki¹, ¹Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ²Department of Inflammation and Pain Control Research, Toho University School of Medicine, Tokyo, Japan
Background/Purpose: Epstein-Barr virus (EBV) infection causes various malignant tumors such as B cell lymphoma and epithelial cell cancer. Previous reports showed several variants in carboxyl-terminal…
Abstract Number: 541 • 2017 ACR/ARHP Annual Meeting
Decreasing Trend of Serious Infections Incidence Rate Along Years in Rheumatoid Arthritis Patients Exposed to Biologics. Data from Two Latin America Registries
Roberto Ranza¹, Ieda Maria Magalhães Laurindo², Georges Christopoulos², Gimena Gomez³, Enrique R Soriano⁴, Miguel Angel Descalzo⁵ and Maria de la Vega⁶, ¹on behalf of the BiobadaBrasil study group, Sociedade Brasileira de Reumatologia, Uberlandia, Brazil, ²on behalf of the BiobadaBrasil study group, Sociedade Brasileira de Reumatologia, São Paulo, Brazil, ³on behalf of BiobadaSar study group, Sociedad Argentina de Reumatologia, Buenos Aires, Argentina, ⁴Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Research Unit, Fundacion piel sana AEDV, Madrid, Spain, Madrid, Spain, ⁶on behalf of BiobadaSar study group, Sociedad Argentina de Reumatologia, Buenos aires, Argentina
Background/Purpose: Infections are the most frequent and concerning serious adverse events related to rheumatoid arthritis (RA) treatment with biologic drugs (bDMARDs). Their safety profile might…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].